ABT - Abbott Laboratories Stock Price, News & Analysis

$55.80 -0.32 (-0.57 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$56.12
Today's Range$55.57 - $56.15
52-Week Range$37.38 - $56.69
Volume3.55 million shs
Average Volume6.64 million shs
Market Capitalization$97.68 billion
P/E Ratio23.29
Dividend Yield1.92%
Beta1.06

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410

Debt

Debt-to-Equity Ratio0.72%
Current Ratio2.69%
Quick Ratio2.26%

Price-To-Earnings

Trailing P/E Ratio23.29
Forward P/E Ratio22.41
P/E Growth2.1

Sales & Book Value

Annual Sales$20.85 billion
Price / Sales4.66
Cash Flow$2.77 per share
Price / Cash20.13
Book Value$18.51 per share
Price / Book3.01

Dividend

Annual Dividend$1.06
Dividend Yield1.9%

Profitability

Trailing EPS$1.27
Net Income$1.40 billion
Net Margins8.37%
Return on Equity13.98%
Return on Assets6.09%

Miscellaneous

Employees75,000
Outstanding Shares1,740,600,000

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, September 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.90%. The ex-dividend date is Thursday, October 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) released its quarterly earnings results on Wednesday, October, 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.65 by $0.01. The healthcare product maker had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business's quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 earnings per share. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its fourth quarter earnings guidance on Wednesday, October, 18th. The company provided earnings per share guidance of $0.72-0.74 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.73.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

14 analysts have issued twelve-month target prices for Abbott Laboratories' stock. Their predictions range from $42.00 to $68.00. On average, they expect Abbott Laboratories' share price to reach $57.64 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

What are Wall Street analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

  • 1. According to Zacks Investment Research, "Abbott exceeded the Zacks Consensus Estimate on both earnings and sales front in the third quarter. We are optimistic about the strong and consistent EPD and Medical Devices performance. However, these were to some extent offset by sluggish Nutrition business. The company continues to benefit from the recently completed St. Jude Medical buyout. Meanwhile, Alere acquisition close is an upside too. Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received the FDA approval. Also, it has received approval for MR-conditional labeling for Ellipse ICD. Also, emerging market performance remains promising on several new strategic developments. Hence, in the past three months, Abbott is trading above the broader industry. On the flip side, sluggish pediatric nutrition business in some global markets continues to dent growth. Also the economic problems in Venezuela are expected to remain unresolved." (10/31/2017)
  • 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

  • Miles D. White, Chairman of the Board, Chief Executive Officer (Age 62)
  • Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance (Age 47)
  • Michael T. Rousseau, President - Cardiovascular and Neuromodulation (Age 61)
  • Hubert L. Allen, Executive Vice President, General Counsel, Secretary (Age 51)
  • Stephen R. Fussell, Executive Vice President - Human Resources (Age 59)
  • Brian J. Blaser, Executive Vice President - Diagnostics Products (Age 52)
  • John M. Capek Ph.D., Executive Vice President - Ventures (Age 55)
  • Robert B. Ford, Executive Vice President - Medical Devices (Age 43)
  • Heather L. Mason, Executive Vice President - Nutritional Products (Age 56)
  • Roger M Bird, Senior Vice President - U.S. Nutrition (Age 60)

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.87%), Macquarie Group Ltd. (0.80%), Flossbach Von Storch AG (0.64%), Diamond Hill Capital Management Inc. (0.64%), Dimensional Fund Advisors LP (0.62%) and Independent Franchise Partners LLP (0.58%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Flossbach Von Storch AG, American Century Companies Inc., Bank of New York Mellon Corp, APG Asset Management N.V., Diamond Hill Capital Management Inc., Dimensional Fund Advisors LP and Boston Partners. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Harding Loevner LP, DSM Capital Partners LLC, Point72 Asset Management L.P., Jennison Associates LLC, Janus Henderson Group PLC, Russell Investments Group Ltd., Crossmark Global Holdings Inc. and Great West Life Assurance Co. Can. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $55.80.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $97.68 billion and generates $20.85 billion in revenue each year. The healthcare product maker earns $1.40 billion in net income (profit) each year or $1.27 on an earnings per share basis. Abbott Laboratories employs 75,000 workers across the globe.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (ABT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  597 (Vote Outperform)
Underperform Votes:  449 (Vote Underperform)
Total Votes:  1,046
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Abbott Laboratories (NYSE:ABT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $57.64 (3.30% upside)

Consensus Price Target History for Abbott Laboratories (NYSE:ABT)

Price Target History for Abbott Laboratories (NYSE:ABT)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017Barclays PLCReiterated RatingOverweightN/AView Rating Details
10/19/2017Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
10/19/2017BMO Capital MarketsReiterated RatingMarket PerformN/AView Rating Details
10/19/2017Cowen and CompanySet Price TargetBuy$55.00 -> $68.00N/AView Rating Details
10/19/2017Stifel NicolausBoost Price TargetBuy -> Buy$58.00 -> $63.00N/AView Rating Details
10/19/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$55.00 -> $60.00N/AView Rating Details
10/19/2017Jefferies Group LLCReiterated RatingBuy$65.00N/AView Rating Details
10/6/2017J P Morgan Chase & CoInitiated CoverageNeutral -> Neutral$60.00N/AView Rating Details
10/4/2017Bank of America CorporationReiterated RatingBuy$56.00 -> $60.00N/AView Rating Details
9/28/2017Wells Fargo & CompanyBoost Price TargetOutperform$57.00 -> $64.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
6/29/2017GuggenheimInitiated CoverageBuy$58.00LowView Rating Details
6/21/2017BTIG ResearchInitiated CoverageBuy$56.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$45.00LowView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Abbott Laboratories (NYSE:ABT)

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Earnings History by Quarter for Abbott Laboratories (NYSE ABT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/23/2018$0.73N/AView Earnings Details
10/18/20179/30/2017$0.65$0.66$6.72 billion$6.83 billionViewN/AView Earnings Details
7/20/2017Q2 2017$0.60$0.62$6.63 billion$6.64 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.43
2018 EPS Consensus Estimate: $2.84
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20173$0.59$0.61$0.60
Q3 20173$0.64$0.68$0.66
Q4 20173$0.72$0.73$0.72
Q1 20183$0.56$0.58$0.57
Q2 20183$0.71$0.72$0.72
Q3 20183$0.76$0.77$0.76
Q4 20183$0.78$0.80$0.79
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Abbott Laboratories (NYSE:ABT)

Most Recent Dividend:11/15/2017
Annual Dividend:$1.06
Dividend Yield:1.90%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:83.47% (Trailing 12 Months of Earnings)
42.57% (Based on This Year's Estimates)
37.46% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE ABT)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/15/2017quarterly$0.272.05%10/12/201710/13/201711/15/2017
6/9/2017quarterly$0.272.25%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.272.36%4/11/20174/14/20175/15/2017
12/9/2016quarterly$0.272.7%1/11/20171/13/20172/15/2017
9/15/2016quarterly$0.262.48%10/12/201610/14/201611/15/2016
6/10/2016quarterly$0.262.75%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.262.66%4/13/20164/15/20165/16/2016
12/11/2015quarterly$0.262.32%1/13/20161/15/20162/16/2016
9/17/2015quarterly$0.242.22%10/13/201510/15/201511/15/2015
6/12/2015quarterly$0.242%7/13/20157/15/20158/15/2015
2/20/2015quarterly$0.242.03%4/13/20154/15/20155/15/2015
12/12/2014quarterly$0.242.21%1/13/20151/15/20152/13/2015
9/11/2014quarterly$0.222.07%10/10/201410/15/201411/15/2014
6/13/2014quarterly$0.222.21%7/11/20147/15/20148/15/2014
2/21/2014quarterly$0.222.26%4/11/20144/15/20145/15/2014
10/16/2013quarterly$0.222.37%1/13/20141/15/20142/15/2014
9/12/2013quarterly$0.141.61%10/10/201310/15/201311/15/2013
6/14/2013quarterly$0.141.52%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.141.61%4/11/20134/15/20135/15/2013
12/14/2012quarterly$0.140.86%1/11/20131/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE ABT)

Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 69.99%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Insider Trades by Quarter for Abbott Laboratories (NYSE ABT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2017Alejandro D WellischInsiderSell2,153$55.86$120,266.58View SEC Filing  
11/17/2017Brian J BlaserInsiderSell23,866$55.55$1,325,756.30View SEC Filing  
11/14/2017Daniel Gesua Sive SalvadoriInsiderSell71,157$55.00$3,913,635.00View SEC Filing  
10/23/2017Daniel Gesua Sive SalvadoriEVPSell96,603$56.21$5,430,054.63View SEC Filing  
9/26/2017Daniel Gesua Sive SalvadoriInsiderSell62,460$52.95$3,307,257.00View SEC Filing  
9/22/2017Jaime ContrerasInsiderSell52,700$51.97$2,738,819.00View SEC Filing  
8/16/2017Stephen R FussellInsiderSell196,550$49.50$9,729,225.00View SEC Filing  
8/1/2017Sharon J BrackenInsiderSell2,000$49.16$98,320.00View SEC Filing  
7/27/2017Brian J BlaserInsiderSell15,000$50.00$750,000.00View SEC Filing  
7/25/2017Hubert L AllenInsiderSell4,600$50.79$233,634.00View SEC Filing  
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.44View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.00View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.00View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Abbott Laboratories (NYSE ABT)

Source:
DateHeadline
Should You Sell Abbott Laboratories (ABT) At This PE Ratio?Should You Sell Abbott Laboratories (ABT) At This PE Ratio?
finance.yahoo.com - November 23 at 3:20 PM
ValuEngine Upgrades Abbott Laboratories (ABT) to BuyValuEngine Upgrades Abbott Laboratories (ABT) to Buy
www.americanbankingnews.com - November 23 at 12:46 AM
Alejandro D. Wellisch Sells 2,153 Shares of Abbott Laboratories (ABT) StockAlejandro D. Wellisch Sells 2,153 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - November 22 at 8:23 PM
Trade of the Day: Abbott Laboratories (ABT) - Investorplace.comTrade of the Day: Abbott Laboratories (ABT) - Investorplace.com
investorplace.com - November 21 at 3:58 PM
Earnings Momentum Make Abbott Laboratories (ABT) a Buy - Investorplace.comEarnings Momentum Make Abbott Laboratories (ABT) a Buy - Investorplace.com
investorplace.com - November 21 at 3:58 PM
Earnings Momentum Make Abbott Laboratories (ABT) a BuyEarnings Momentum Make Abbott Laboratories (ABT) a Buy
investorplace.com - November 21 at 10:33 AM
Abbott Laboratories (ABT) Insider Brian J. Blaser Sells 23,866 SharesAbbott Laboratories (ABT) Insider Brian J. Blaser Sells 23,866 Shares
www.americanbankingnews.com - November 20 at 7:37 PM
Roche To Acquire Viewics For Laboratory AnalyticsRoche To Acquire Viewics For Laboratory Analytics
seekingalpha.com - November 20 at 3:45 PM
ETFs with exposure to Abbott Laboratories : November 20, 2017ETFs with exposure to Abbott Laboratories : November 20, 2017
finance.yahoo.com - November 20 at 3:45 PM
Trade of the Day: Abbott Laboratories (ABT)Trade of the Day: Abbott Laboratories (ABT)
investorplace.com - November 20 at 9:00 AM
Daniel Gesua Sive Salvadori Sells 71,157 Shares of Abbott Laboratories (ABT) StockDaniel Gesua Sive Salvadori Sells 71,157 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - November 16 at 7:47 PM
How These Rivals Could Take A Chunk Of Medtronic's Heart-Unit SalesHow These Rivals Could Take A Chunk Of Medtronic's Heart-Unit Sales
finance.yahoo.com - November 16 at 3:35 PM
Breakfast Technical Briefing on Medical Equipment Stocks -- Hologic, Nxstage Medical, Wright Medical, and Abbott LabsBreakfast Technical Briefing on Medical Equipment Stocks -- Hologic, Nxstage Medical, Wright Medical, and Abbott Labs
www.bizjournals.com - November 16 at 10:36 AM
Horizon Pharma PLC (HZNP) and Abbott Laboratories (ABT) Critical ContrastHorizon Pharma PLC (HZNP) and Abbott Laboratories (ABT) Critical Contrast
www.americanbankingnews.com - November 15 at 11:38 AM
High-Level Earnings Momentum Keep Abbott Laboratories (ABT) a BuyHigh-Level Earnings Momentum Keep Abbott Laboratories (ABT) a Buy
investorplace.com - November 14 at 10:28 AM
Abbott Laboratories (ABT) Expected to Announce Quarterly Sales of $7.38 BillionAbbott Laboratories (ABT) Expected to Announce Quarterly Sales of $7.38 Billion
www.americanbankingnews.com - November 14 at 6:02 AM
Absolute Reports Fiscal 2018 First Quarter Financial ResultsAbsolute Reports Fiscal 2018 First Quarter Financial Results
www.businesswire.com - November 13 at 5:22 PM
Abbott Laboratories (ABT) Expected to Post Earnings of $0.73 Per ShareAbbott Laboratories (ABT) Expected to Post Earnings of $0.73 Per Share
www.americanbankingnews.com - November 12 at 5:42 PM
ETFs with exposure to Abbott Laboratories : November 9, 2017ETFs with exposure to Abbott Laboratories : November 9, 2017
finance.yahoo.com - November 9 at 4:16 PM
Abbott Laboratories :ABT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017Abbott Laboratories :ABT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:21 PM
Abbott Laboratories’ (ABT) High-Level Sales Growth Make it a BuyAbbott Laboratories’ (ABT) High-Level Sales Growth Make it a Buy
investorplace.com - November 7 at 4:49 PM
Abbott Laboratories’ (ABT) High-Level Sales Growth Make it a BuyAbbott Laboratories’ (ABT) High-Level Sales Growth Make it a Buy
investorplace.com - November 7 at 10:04 AM
Abbotts MitraClip OKd in Japan - Seeking AlphaAbbott's MitraClip OK'd in Japan - Seeking Alpha
seekingalpha.com - November 6 at 9:07 PM
Abbotts MitraClip Approved as First Transcatheter Mitral Valve Repair Device in JapanAbbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan
finance.yahoo.com - November 6 at 4:07 PM
Abbotts Generic Pharmaceutical Business To Continue Growth Led By Emerging MarketsAbbott's Generic Pharmaceutical Business To Continue Growth Led By Emerging Markets
finance.yahoo.com - November 6 at 4:07 PM
Abbott Laboratories (ABT) Given Consensus Rating of "Buy" by BrokeragesAbbott Laboratories (ABT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 8:08 AM
Heart stents fail to ease chest pain - NYT - Seeking AlphaHeart stents fail to ease chest pain - NYT - Seeking Alpha
seekingalpha.com - November 2 at 3:25 PM
Abbott Announces FDA Clearance for its Alinity™ ci-series Next-generation Diagnostic SystemsAbbott Announces FDA Clearance for its Alinity™ ci-series Next-generation Diagnostic Systems
finance.yahoo.com - October 31 at 4:31 PM
Abbott Laboratories (ABT) Upgraded to Buy at Zacks Investment ResearchAbbott Laboratories (ABT) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - October 31 at 4:16 PM
Abbott Laboratories (ABT) a Buy on Healthy Sales GrowthAbbott Laboratories (ABT) a Buy on Healthy Sales Growth
investorplace.com - October 31 at 10:00 AM
Abbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in EuropeAbbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe
finance.yahoo.com - October 30 at 3:25 PM
Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease with XIENCE Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart SurgeryAnalysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease with XIENCE Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery
finance.yahoo.com - October 30 at 3:25 PM
Abbotts Inviting New Allure - Seeking AlphaAbbott's Inviting New Allure - Seeking Alpha
seekingalpha.com - October 27 at 5:31 PM
Chemed (CHE) Beats on Q3 Earnings & Revenues, View RevisedChemed (CHE) Beats on Q3 Earnings & Revenues, View Revised
finance.yahoo.com - October 27 at 5:31 PM
Align Technology (ALGN) Q3 Earnings Top on Invisalign SalesAlign Technology (ALGN) Q3 Earnings Top on Invisalign Sales
finance.yahoo.com - October 27 at 5:31 PM
Integra LifeSciences (IART) Misses on Q3 Earnings & RevenuesIntegra LifeSciences (IART) Misses on Q3 Earnings & Revenues
finance.yahoo.com - October 27 at 5:31 PM
Boston Scientific Dives As Pacemaker Sales Miss On Abbott RivalryBoston Scientific Dives As Pacemaker Sales Miss On Abbott Rivalry
finance.yahoo.com - October 26 at 11:38 AM
McKesson (MCK) Beats Earnings & Revenue Estimates in Q2McKesson (MCK) Beats Earnings & Revenue Estimates in Q2
finance.yahoo.com - October 26 at 11:38 AM
Boston Scientific's (BSX) Q3 Earnings In Line, Guidance UpBoston Scientific's (BSX) Q3 Earnings In Line, Guidance Up
finance.yahoo.com - October 26 at 11:38 AM
Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues LagCardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag
finance.yahoo.com - October 26 at 11:38 AM
Daniel Gesua Sive Salvadori Sells 96,603 Shares of Abbott Laboratories (ABT) StockDaniel Gesua Sive Salvadori Sells 96,603 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - October 25 at 5:24 PM
Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises GuidanceIllumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance
finance.yahoo.com - October 25 at 4:12 PM
Accuray's (ARAY) Q1 Loss in Line, Revenues Beat EstimatesAccuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
finance.yahoo.com - October 25 at 4:12 PM
ETFs with exposure to Abbott Laboratories : October 25, 2017ETFs with exposure to Abbott Laboratories : October 25, 2017
finance.yahoo.com - October 25 at 4:12 PM
NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance CutNuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut
finance.yahoo.com - October 25 at 4:12 PM
Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 ViewWalgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View
finance.yahoo.com - October 25 at 4:12 PM
LabCorp (LH) Beats Q3 Earnings Estimates, Raises GuidanceLabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance
finance.yahoo.com - October 25 at 4:12 PM
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance UpThermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
finance.yahoo.com - October 25 at 4:12 PM
Abbott Laboratories (ABT) a Buy on Solid Sales Growth - Investorplace.comAbbott Laboratories (ABT) a Buy on Solid Sales Growth - Investorplace.com
investorplace.com - October 25 at 1:25 AM
Abbott Labs Price Estimate Revised On Operational GrowthAbbott Labs Price Estimate Revised On Operational Growth
finance.yahoo.com - October 24 at 3:21 PM

Social Media

Financials

Chart

Abbott Laboratories (NYSE ABT) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.